Effect of Expansion Media on Functional Characteristics of Bone Marrow-Derived Mesenchymal Stromal Cells

被引:7
作者
Jakl, Viktoria [1 ]
Popp, Tanja [2 ]
Haupt, Julian [2 ,3 ]
Port, Matthias [2 ]
Roesler, Reinhild [4 ]
Wiese, Sebastian [4 ]
Friemert, Benedikt [3 ]
Rojewski, Markus T. [1 ,5 ,6 ]
Schrezenmeier, Hubert [1 ,5 ,6 ]
机构
[1] Univ Hosp Ulm, Inst Transfus Med, D-89081 Ulm, Germany
[2] Bundeswehr Inst Radiobiol, D-80937 Munich, Germany
[3] Army Hosp Ulm, Clin Trauma Surg & Orthoped, Ulm, Germany
[4] Ulm Univ, Med Ctr, Core Unit Mass Spectrometry & Prote, D-89081 Ulm, Germany
[5] German Red Cross Blood Donat Serv Baden Wurttember, Inst Clin Transfus Med & Immunogenet Ulm, D-89081 Ulm, Germany
[6] Univ Hosp Ulm, D-89081 Ulm, Germany
关键词
mesenchymal stromal cells; mesenchymal stem cells; media; serum-free; xenogeneic-free; platelet lysate; HEPATOCYTE GROWTH-FACTOR; VERSUS-HOST-DISEASE; FETAL BOVINE SERUM; MONOCYTE CHEMOATTRACTANT PROTEIN-1; INSULIN-PRODUCING CELLS; HUMAN PLATELET LYSATE; STEM-CELLS; TGF-BETA; ENDOTHELIAL-CELLS; PROMOTES ANGIOGENESIS;
D O I
10.3390/cells12162105
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The therapeutic efficacy of mesenchymal stromal cells (MSCs) has been shown to rely on their immunomodulatory and regenerative properties. In order to obtain sufficient numbers of cells for clinical applications, MSCs have to be expanded ex vivo. Expansion media with xenogeneic-free (XF) growth-promoting supplements like human platelet lysate (PL) or serum- and xenogeneicfree (SF/XF) formulations have been established as safe and efficient, and both groups provide different beneficial qualities. In this study, MSCs were expanded in XF or SF/XF media as well as in mixtures thereof. MSCs cultured in these media were analyzed for phenotypic and functional properties. MSC expansion was optimal with SF/XF conditions when PL was present. Metabolic patterns, consumption of growth factors, and secretome of MSCs differed depending on the type and concentration of supplement. The lactate per glucose yield increased along with a higher proportion of PL. Many factors in the supernatant of cultured MSCs showed distinct patterns depending on the supplement (e.g., FGF-2, TGF beta, and insulin only in PL-expanded MSC, and leptin, sCD40L PDGF-AA only in SF/XF-expanded MSC). This also resulted in changes in cell characteristics like migratory potential. These findings support current approaches where growth media may be utilized for priming MSCs for specific therapeutic applications.
引用
收藏
页数:31
相关论文
共 184 条
[31]   Targeting Nonhealing Ulcers of Lower Extremity in Human Through Autologous Bone Marrow-Derived Mesenchymal Stem Cells [J].
Dash, Nihar Ranjan ;
Dash, Surjya Narayan ;
Routray, Padmanav ;
Mohapatra, Sribatsha ;
Mohapatra, Prakash C. .
REJUVENATION RESEARCH, 2009, 12 (05) :359-366
[32]   Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3 [J].
De Becker, Ann ;
Van Hummelen, Paul ;
Bakkus, Marleen ;
Vande Broek, Isabelle ;
De Wever, Joke ;
De Waele, Marc ;
Van Riet, Ivan .
HAEMATOLOGICA, 2007, 92 (04) :440-449
[33]   A serum-free medium formulation efficiently supports isolation and propagation of canine adipose-derived mesenchymal stem/stromal cells [J].
Devireddy, Laxminarayana R. ;
Myers, Michael ;
Screven, Rudell ;
Liu, Zhuoming ;
Boxer, Lynne .
PLOS ONE, 2019, 14 (02)
[34]   Synthetic Surface for Expansion of Human Mesenchymal Stem Cells in Xeno-Free, Chemically Defined Culture Conditions [J].
Dolley-Sonneville, Paula J. ;
Romeo, Lori E. ;
Melkoumian, Zara K. .
PLOS ONE, 2013, 8 (08)
[35]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[36]   Intracellular role of IL-6 in mesenchymal stromal cell immunosuppression and proliferation [J].
Dorronsoro, Akaitz ;
Lang, Valerie ;
Ferrin, Izaskun ;
Fernandez-Rueda, Jon ;
Zabaleta, Lorea ;
Perez-Ruiz, Estibaliz ;
Sepulveda, Pilar ;
Trigueros, Cesar .
SCIENTIFIC REPORTS, 2020, 10 (01)
[37]   Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation [J].
Dotoli, G. M. ;
De Santis, G. C. ;
Orellana, M. D. ;
de Lima Prata, K. ;
Caruso, S. R. ;
Fernandes, T. R. ;
Rensi Colturato, V. A. ;
Kondo, A. T. ;
Hamerschlak, N. ;
Simoes, B. P. ;
Covas, D. T. .
BONE MARROW TRANSPLANTATION, 2017, 52 (06) :859-862
[38]   Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor [J].
Duan, HF ;
Wu, CT ;
Wu, DL ;
Lu, Y ;
Liu, HJ ;
Ha, XQ ;
Zhang, QW ;
Wang, H ;
Jia, XX ;
Wang, LS .
MOLECULAR THERAPY, 2003, 8 (03) :467-474
[39]   Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells [J].
Ellis, MJC ;
Leav, BA ;
Yang, ZJ ;
Rasmussen, A ;
Pearce, A ;
Zweibel, JA ;
Lippman, ME ;
Cullen, KJ .
MOLECULAR ENDOCRINOLOGY, 1996, 10 (03) :286-297
[40]   Follistatin Effects in Migration, Vascularization, and Osteogenesis in vitro and Bone Repair in vivo [J].
Fahmy-Garcia, Shorouk ;
Farrell, Eric ;
Witte-Bouma, Janneke ;
Robbesom-van den Berge, Iris ;
Suarez, Melva ;
Mumcuoglu, Didem ;
Wailes, Heike ;
Kluijtmans, Sebastiaan G. J. M. ;
van der Eerden, Bram C. J. ;
van Osch, Gerjo J. V. M. ;
van Leeuwen, Johannes P. T. M. ;
van Driel, Marjolein .
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2019, 7 (MAR)